NEW YORK (GenomeWeb News) – Transgenomic today said that it expects to raise $7 million in gross proceeds from the sale of 1,443,297 convertible preferred shares.

The Omaha, Neb.-based molecular diagnostics company said that it will sell the shares of Series B convertible preferred shares to affiliates of investment firm Third Security at $4.85 per share. The preferred shares will be convertible into common shares of Transgenomic on a one-for-one basis, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.